ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
23andMe Holding Company

23andMe Holding Company (ME)

3,24
-0,10
(-2,99%)
Geschlossen 18 Dezember 10:00PM
3,3195
0,0795
(2,45%)
Nach Börsenschluss: 1:59AM

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
3,24
Gebot
3,23
Fragen
3,64
Volumen
192.633
3,17 Tagesbereich 3,38
2,655 52-Wochen-Bereich 19,378
Marktkapitalisierung
Handelsende
3,34
Handelsbeginn
3,36
Letzte Trade
5
@
3.39
Letzter Handelszeitpunkt
Finanzvolumen
US$ 625.473
VWAP
3,247
Durchschnittliches Volumen (3 Mio.)
1.499.011
Ausgegebene Aktien
26.117.997
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,13
Gewinn pro Aktie (EPS)
-25,53
Erlöse
219,64M
Nettogewinn
-666,7M

Über 23andMe Holding Company

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic t... 23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Blank Checks
Website
Hauptsitz
Wilmington, Delaware, USA
Gegründet
2021
23andMe Holding Company is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ME. The last closing price for 23andMe was US$3,34. Over the last year, 23andMe shares have traded in a share price range of US$ 2,655 to US$ 19,378.

23andMe currently has 26.117.997 shares in issue. The market capitalisation of 23andMe is US$87,23 million. 23andMe has a price to earnings ratio (PE ratio) of -0.13.

ME Neueste Nachrichten

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a...

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second...

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all...

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the...

23andMe to Report Q2 FY2025 Financial Results

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.64-16.49484536083.883.92943.241930113.44133635CS
40.5319.5571955722.714.172.6553964953.44292802CS
12-3.524-52.09934949736.7647.882.65514990115.85444527CS
26-4.76-59.5810.8062.65524586547.12932088CS
52-15.598-82.80072194518.83819.3782.655436845810.66335599CS
156-139.56-97.731092437142.8150.82.655353064236.5065247CS
260-128.56-97.5417298938131.8273.62.655279265152.18595135CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
NUKKNukkleus Inc
US$ 11,655
(738,49%)
174,4M
PRTGPortage Biotech Inc
US$ 8,8678
(172,86%)
36,61M
OPTXSyntec Optics Holdings Inc
US$ 3,55
(99,44%)
93,16M
PTPIPetros Pharmaceuticals Inc
US$ 0,4976
(86,37%)
63,49M
LUXHLuxUrban Hotels Inc
US$ 0,849899
(59,67%)
29,52M
VCNXVaccinex Inc
US$ 1,41
(-61,37%)
758,95k
TNYATenaya Therapeutics Inc
US$ 1,395
(-51,56%)
42,45M
ORKTOrangeKloud Technology Inc
US$ 2,14
(-41,85%)
2,29M
RVPHReviva Pharmaceuticals Holdings Inc
US$ 1,395
(-39,35%)
18,16M
DBGIDigital Brands Group Inc
US$ 2,46
(-37,88%)
805,23k
RIMEAlgorhythm Holdings Inc
US$ 0,0877
(8,27%)
1,13B
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,335
(-36,79%)
1,02B
GOEVCanoo Inc
US$ 0,118
(7,08%)
388,43M
NVDANVIDIA Corporation
US$ 130,39
(-1,22%)
259,4M
XTIAXTI Aerospace Inc
US$ 0,0442
(8,33%)
222,55M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock